Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Covid-19: Govt considering 2nd doses with different vaccine

Bangladesh has so far administered over 5.81 million doses, with about 3.87 million people having received their second dose

Update : 19 May 2021, 11:11 PM

The health authorities are considering the possibility of using a different Covid-19 vaccine to give second doses to those who are waiting for them after receiving their first doses of the AstraZeneca vaccine.

Last week the Directorate General of Health Services had said vaccine recipients would need the same vaccine for their second dose. However, the government’s position has now changed.

At a press conference on Wednesday afternoon, DGHS Line Director (Non-communicable disease control) Dr Robed Amin said the government was now considering the use of different vaccines for second doses due to uncertainty over the arrival of more AstraZeneca vaccines and also because some European countries had already started mixing doses.

“The National Technical Advisory Committee (NTAC) on Covid-19 has already been asked to give its recommendation on using different vaccines for first and second doses,” added Dr Robed Amin, who is also spokesperson for Covid-19 management at DGHS. 

Although there is a lack of data on mixing doses, a limited study in Spain found strong evidence of antibody development among the participants. The administering of the doses was deemed safe and effective, the DGHS line director further said.

According to Reuters, a total of about 670 volunteers between the ages of 18-59, who had already received a first dose of the AstraZeneca vaccine, participated in the Spanish study, with 450 of them given a Pfizer dose.

Onlg 1.7% of the participants reported severe side effects, and none with symptoms that could be considered serious, said experts as quoted in the Reuters report.   

Bangladesh has so far administered over 5.81 million doses, with about 3.87 million people having received their second dose. The DGHS reportedly has around 600,000 doses remaining in stock.

As matters stand, over 1.3 million people who have received their first dose will be left waiting for their second.

The global scene

On April 1, Germany became the first European country to recommend that people under the age of 60, who had received a first dose of the AstraZeneca vaccine, should receive a different vaccine as their second dose. Within a week, France followed suit and made a similar recommendation.

Norway became the third country to recommend mixing doses of the Covid-19 vaccine in late April, and several other European countries are on track to do the same. The United Kingdom and Canada are also examining the evidence on dose mixing.

However, the European Medicines Agency (EMA) last month advised using the same vaccine for both doses as there was inadequate evidence on the effectiveness of mixing doses.

Infectious diseases experts, pharmacologists and pathogen experts said the mixing of different vaccine types is known as a heterologous prime-boost vaccination. It started in the 1990s as a strategy tested by HIV researchers.

Global interest in heterologous prime-boost Covid-19 vaccination is rising every day as a potential measure against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-outs, they added.

Dr Abdur Rahman, dean of the pharmacy department at Dhaka University, said: “Although scientists lack adequate data on mixing, it can be said from our experience of virus behaviour that it may have some benefits.

“Russia’s Sputnik V as well as the Johnson & Johnson and AstraZeneca vaccines use an adenovirus in different ways, while SinoVac and Sinopharm are inactivated vaccines. Pfizer and Moderna are mRNA vaccines. They all have the same goal of developing antibodies, but they achieve it in different ways.

“If you mix different types of vaccines, you may increase immune system response and it could be more effective against emerging variants of the coronavirus,” he added.

Top Brokers